JP5478495B2 - アドレナリン作動性α−1受容体アンタゴニストの新規な治療的使用 - Google Patents
アドレナリン作動性α−1受容体アンタゴニストの新規な治療的使用 Download PDFInfo
- Publication number
- JP5478495B2 JP5478495B2 JP2010526392A JP2010526392A JP5478495B2 JP 5478495 B2 JP5478495 B2 JP 5478495B2 JP 2010526392 A JP2010526392 A JP 2010526392A JP 2010526392 A JP2010526392 A JP 2010526392A JP 5478495 B2 JP5478495 B2 JP 5478495B2
- Authority
- JP
- Japan
- Prior art keywords
- bladder
- alfuzosin
- adrenergic
- receptor antagonists
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
膀胱炎誘導のために、雄Sprague−DawleyラットおよびSwissマウスにCYP(150mg/kg、i.p.)またはこのビヒクル(0.9%NaCl)を投与した。48時間後に、膀胱を取り出し、運動応答測定のために器官浴に入れた。CYP投与から90分後に、悶え挙動および血漿中蛋白質血管外遊出を調べた。
ラット膀胱の切片を末端麻酔動物から採取し、器官浴中に設置し、平衡期間の後、アトロピン(1μM)の不存在下および存在下で、電場刺激(EFS、5Hz、1ms幅、10V)に対するeNANC収縮応答を調べる(Rigoni et al.,2003,Br J Pharmacol,138,977−85)。これらの実験条件におけるEFSによって生じた収縮は、一次感覚ニューロンの末端から放出されたSPおよびNKAによって全部が媒介されている。EFSに対するeNANC応答は60分の間隔で再現可能であった。EFSに対するeNANC応答についてのアルフゾシンまたはこのビヒクルの効果を平行実験で調べた。各実験の最初または最後において、組織をカルバコール(1μM)で検証した。アルフゾシンの効果を、シクロホスファミドで処理したラットから得られた膀胱片においても調べた。
シクロホスファミドの腹腔内投与(150mg/kg、48時間前)は、膀胱の能力および増大した排尿の頻度を減少させることが知られている(Maggi et al.,1992,J Auton Nerv Syst,38,201−8)。シクロホスファミドのこれらの効果は、成体としてのカプサイシンで予備処理されたラットにおいてなくなった(Maggi et al.,1992,J Auton Nerv Syst,38,201−8)。このようにして、シクロホスファミドに対する炎症性応答は、神経原性炎症メカニズムによって媒介される。
エバンスブルー色素を用いて、血漿血管外遊出を測定した。頚静脈での色素の注射(5秒間にわたる30mg/kg i.v.)直後に炎症性刺激物を与えた。エバンスブルーの注射後に必要に応じて、胸を10分間、または異なる時間間隔で開き、動物にリン酸緩衝液を3分間灌流した。膀胱、尿道および前立腺を取り出し、ブロットし、秤量した。次いで、組織を3mlのホルムアミド中に50℃にて18時間入れて、血管外遊出したエバンスブルー色素を抽出した。気管および気管支から血管外遊出したエバンスブルーの量を、分光光度計を用いて測定し、ng/mg湿潤重量として表した。
代表的な例として、錠剤の形態の本発明の化合物の単位投与形態は以下の成分を含むことができる。
アルフゾシン塩酸塩 5mg
ラクトース 122mg
マイクロクリスタリンセルロース 36.0mg
ナトリウムカルボキシメチル澱粉 7.0mg
ポリビドン 9mg
ステアリン酸マグネシウム 1.0mg
Claims (5)
- 炎症性膀胱の治療および/または予防用の医薬の調製のためのアルフゾシンまたはこの医薬的に許容される塩の使用。
- 前記炎症性膀胱が、間質性膀胱炎に由来するか、またはこれに関連する、請求項1に記載の使用。
- 該アルフゾシンが、アルフゾシン塩酸塩である、請求項1または2に記載の使用。
- 男性患者での治療および/または予防のための、請求項1から3のいずれか一項に記載の使用。
- 有効成分として、アルフゾシンまたはこの医薬的に許容される塩を含む、炎症性膀胱の治療および/もしくは予防のための医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97532407P | 2007-09-26 | 2007-09-26 | |
EP07291148.0 | 2007-09-26 | ||
US60/975,324 | 2007-09-26 | ||
EP07291148A EP2042179A1 (en) | 2007-09-26 | 2007-09-26 | Novel therapeutic uses of adrenergic alpha-1 receptor antagonists |
PCT/IB2008/003126 WO2009040671A1 (en) | 2007-09-26 | 2008-09-24 | Novel therapeutic uses of adrenergic alpha-1 receptor antagonists |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010540511A JP2010540511A (ja) | 2010-12-24 |
JP2010540511A5 JP2010540511A5 (ja) | 2011-09-15 |
JP5478495B2 true JP5478495B2 (ja) | 2014-04-23 |
Family
ID=38754714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010526392A Expired - Fee Related JP5478495B2 (ja) | 2007-09-26 | 2008-09-24 | アドレナリン作動性α−1受容体アンタゴニストの新規な治療的使用 |
Country Status (15)
Country | Link |
---|---|
US (1) | US8492396B2 (ja) |
EP (2) | EP2042179A1 (ja) |
JP (1) | JP5478495B2 (ja) |
AR (1) | AR068825A1 (ja) |
AT (1) | ATE524185T1 (ja) |
CY (1) | CY1112203T1 (ja) |
DK (1) | DK2203170T3 (ja) |
ES (1) | ES2373354T3 (ja) |
HR (1) | HRP20110919T1 (ja) |
ME (1) | ME01259B (ja) |
PL (1) | PL2203170T3 (ja) |
PT (1) | PT2203170E (ja) |
RS (1) | RS52069B (ja) |
SI (1) | SI2203170T1 (ja) |
WO (1) | WO2009040671A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020015377A1 (zh) * | 2018-07-18 | 2020-01-23 | 温州医科大学 | 一种治疗近视的方法及制备药物的应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2582513B1 (fr) * | 1985-05-28 | 1988-08-05 | Synthelabo | Compositions pharmaceutiques contenant de l'alfuzosine |
US20020143007A1 (en) * | 1996-02-02 | 2002-10-03 | Garvey David S. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use |
CA2295572C (en) * | 1997-07-10 | 2010-07-06 | Therakos, Inc. | Treatment of inflammatory disorders of the bowel and urinary bladder |
CZ20032031A3 (cs) * | 2001-01-26 | 2003-12-17 | Schering Corporation | Farmaceutický prostředek |
DE60234318D1 (de) * | 2001-02-08 | 2009-12-24 | Ono Pharmaceutical Co | Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors |
US6987129B2 (en) * | 2001-03-06 | 2006-01-17 | Cellegy Pharmaceuticals, Inc. | Compounds and methods for the treatment of urogenital disorders |
US20030060513A1 (en) * | 2001-09-27 | 2003-03-27 | Arneric Stephen P. | Pharmaceutical composition |
US20050261344A1 (en) * | 2002-08-14 | 2005-11-24 | Jones Charles R | Treatment of lower urinary tract symptoms associated with overactive bladder in men and women |
EP1644369A2 (en) * | 2003-07-02 | 2006-04-12 | F. Hoffmann-La Roche Ag | Arylamine-substituted quinazolinone compounds |
US20070093493A1 (en) * | 2005-10-12 | 2007-04-26 | Lilly Icos Llc | Treatment of benign prostatic hypertrophy and lower urinary tract symptoms |
-
2007
- 2007-09-26 EP EP07291148A patent/EP2042179A1/en not_active Withdrawn
-
2008
- 2008-09-24 AR ARP080104131A patent/AR068825A1/es unknown
- 2008-09-24 RS RS20110553A patent/RS52069B/en unknown
- 2008-09-24 JP JP2010526392A patent/JP5478495B2/ja not_active Expired - Fee Related
- 2008-09-24 WO PCT/IB2008/003126 patent/WO2009040671A1/en active Application Filing
- 2008-09-24 ES ES08833688T patent/ES2373354T3/es active Active
- 2008-09-24 PL PL08833688T patent/PL2203170T3/pl unknown
- 2008-09-24 EP EP08833688A patent/EP2203170B1/en active Active
- 2008-09-24 SI SI200830471T patent/SI2203170T1/sl unknown
- 2008-09-24 DK DK08833688.8T patent/DK2203170T3/da active
- 2008-09-24 AT AT08833688T patent/ATE524185T1/de active
- 2008-09-24 PT PT08833688T patent/PT2203170E/pt unknown
- 2008-09-24 ME MEP-2011-204A patent/ME01259B/me unknown
-
2010
- 2010-03-24 US US12/730,559 patent/US8492396B2/en not_active Expired - Fee Related
-
2011
- 2011-12-06 HR HR20110919T patent/HRP20110919T1/hr unknown
- 2011-12-14 CY CY20111101243T patent/CY1112203T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ME01259B (me) | 2013-06-20 |
EP2203170A1 (en) | 2010-07-07 |
PT2203170E (pt) | 2011-12-27 |
CY1112203T1 (el) | 2015-12-09 |
US20110009436A1 (en) | 2011-01-13 |
SI2203170T1 (sl) | 2012-01-31 |
DK2203170T3 (da) | 2012-01-16 |
AR068825A1 (es) | 2009-12-09 |
WO2009040671A4 (en) | 2009-05-28 |
ES2373354T3 (es) | 2012-02-02 |
WO2009040671A1 (en) | 2009-04-02 |
PL2203170T3 (pl) | 2012-02-29 |
JP2010540511A (ja) | 2010-12-24 |
US8492396B2 (en) | 2013-07-23 |
ATE524185T1 (de) | 2011-09-15 |
EP2203170B1 (en) | 2011-09-14 |
RS52069B (en) | 2012-06-30 |
EP2042179A1 (en) | 2009-04-01 |
HRP20110919T1 (hr) | 2012-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4817495B2 (ja) | 外因性カンナビノイドでの痛みの制御 | |
US20050131049A1 (en) | Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence | |
US20040220205A1 (en) | Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof | |
JP2010539235A (ja) | 聴力損失を治療または予防するためのr(+)−n−プロパルギル−1−アミノインダン | |
JP2009535370A (ja) | ジストニアおよびジストニア様症状の予防および治療におけるカリウムチャンネル活性剤 | |
ZA200608241B (en) | Use of peptidic compounds for the prophylaxis and treatment of chronic headache | |
US20220184075A1 (en) | Pharmaceutical composition containing hdac6 inhibitor as active ingredient for prevention or treatment of itching | |
US7834056B2 (en) | Pharmaceutical composition for gout | |
EP1728508A1 (en) | Medicine for prevention or treatment of frequent urination or urinary incontinence | |
MX2014003256A (es) | Uso de hidroxamatos de indolilo e indolinilo para tratar insuficiencia cardiaca o lesion neuronal. | |
IL293013A (en) | Methods for treating inflammatory bowel disease | |
JP5478495B2 (ja) | アドレナリン作動性α−1受容体アンタゴニストの新規な治療的使用 | |
US11376233B2 (en) | Composition, containing sarpogrelate as active ingredient, for preventing or treating sensorineural hearing loss | |
EP3082818A1 (fr) | Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales | |
CN107648236B (zh) | 一种预防或治疗缺血/再灌注损伤的药物组合物及应用 | |
US11986458B1 (en) | Natural and synthetic andrographolides compounds for the treatment of skeletal muscular dystrophies | |
NZ550767A (en) | 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid for treating hair loss and benign prostatic hyperplasia | |
WO2024033946A1 (en) | Compositions and use in methods for treating a cognitive deficit | |
AU2012223521B2 (en) | Treatment of urinary incontinence using nitrone spin traps | |
JP2021521253A (ja) | パラセタモール:アミトリプチリンの固定用量組成物および混合型がん性疼痛を治療するための方法 | |
EP4403181A1 (en) | A medicinal product for use in administering in the treatment, control and/or prevention of pain | |
JP2002524508A (ja) | 新規組成物 | |
JP2002524507A (ja) | 新規組成物 | |
MacDiarmid | How to choose the initial drug treatment for overactive bladder | |
BRPI1103204A2 (pt) | Composição farmacêutica para o tratamento de hiperplasia prostática benigna |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110801 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110801 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130409 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130703 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130710 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131008 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140107 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140205 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140212 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140210 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5478495 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |